Technology | September 22, 2008

Low Energy Beam Delivers High Dose

Intrabeam is a miniature radiation source that delivers high dose, yet is a low energy X-ray used for breast cancer therapy, neurosurgery and other radiation therapies developed by Carl Zeiss Meditec.

The Intrabeam System can be used to treat early stage breast cancer. The radiation dose is administrated to the tumor bed in the operating room, following lumpectomy.

As a minimally invasive technique for stereotactic treatment delivery, following biopsy, the X-ray source probe directs the energy to the target, delivering the dose to the center of the tumor thereby minimizing radiation to healthy tissues.

During treatment delivery, an isotropic dose can be applied directly to the tumor bed, sparing healthy tissue and critical structures, which is said to maximize the amount of dose delivered to the target.

With the precision and control of brachytherapy and the flexibility of intraoperative treatment delivery, Intrabeam offers more options. The miniature X-ray source delivers up to 50kV of energy to the target tissue. Steep dose fall-off ensures that most of the dose stays in the target tissue. Spherical dose delivery that is safely and reliably delivered to tumors and tumor beds. Minimal shielding requirements mean safety for the patient and personnel. Typical treatment takes less than thirty minutes.

This high dose, low energy X-ray requires, according to the manufacturer, minimal shielding for personnel in the operating room, and there is no need to stand behind concrete walls or heavy beam-stopping equipment.

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...